TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7981575

Group type: EXPERIMENTAL
Intervention: Newly diagnosed type 1 diabetes
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Long-standing type 1 diabetes
Number of subjects: 88

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 88

Group type: COMPARATOR
Intervention: Prediabetic groups
Number of subjects: 88

Group type: COMPARATOR
Intervention: Long-standing type 2 diabetes
Number of subjects: 88
Study: 2661750

Group type: EXPERIMENTAL
Intervention: Prone imaging
Number of subjects: 34

Group type: COMPARATOR
Intervention: Supine imaging
Number of subjects: 34
Study: 29603698

Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation (λ = 2.94 μm, 60 mJ, 10 Hz)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no laser irradiation)
Number of subjects: 32
Study: 28880361

Group type: EXPERIMENTAL
Intervention: Mini-pool intravenous immunoglobulin (1 g/kg over 6 to 8 hours)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Standard intravenous immunoglobulin (approximately 1 g/kg as a single dose)
Number of subjects: 72

Group type: COMPARATOR
Intervention: No platelet-enhancing therapy (Control Group C)
Number of subjects: 72
Study: 26118558

Group type: EXPERIMENTAL
Intervention: Home-based limited channel portable monitoring followed by unattended autotitration with CPAP
Number of subjects: 373

Group type: COMPARATOR
Intervention: Laboratory-based pathway with in-laboratory sleep study and CPAP titration
Number of subjects: 373

Group type: COMPARATOR
Intervention: Laboratory arm
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Home arm
Number of subjects: 373
Study: 22960240

Group type: EXPERIMENTAL
Intervention: Individual mirror therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group mirror therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control intervention with restricted view on the affected arm
Number of subjects: 60
Study: 21518250

Group type: EXPERIMENTAL
Intervention: LNS-10gM
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: LNS-20gM
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: LNS-20gNoM
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nutributter
Number of subjects: 18
Study: 19044299

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) administered to 53 patients in the immediate postoperative period
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (non-MMC group) with 52 patients
Number of subjects: 105
Study: 16575109

Group type: EXPERIMENTAL
Intervention: BCG in low dose (0.01 mg)
Number of subjects: 100000

Group type: EXPERIMENTAL
Intervention: BCG in high dose (1.0 mg)
Number of subjects: 100000

Group type: EXPERIMENTAL
Intervention: Danish strain of BCG
Number of subjects: 100000

Group type: EXPERIMENTAL
Intervention: French strain of BCG
Number of subjects: 100000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100000
Study: 12944727

Group type: EXPERIMENTAL
Intervention: Polymyxin B-immobilized fiber (PMX-F) hemoperfusion
Number of subjects: 46

Group type: COMPARATOR
Intervention: Septic patients with encephalopathy
Number of subjects: 46
Study: 10894974

Group type: EXPERIMENTAL
Intervention: 1% colchicine gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hydrophilic gel (placebo)
Number of subjects: 20
Study: 8846745

Group type: EXPERIMENTAL
Intervention: Behavioral program
Number of subjects: 241

Group type: COMPARATOR
Intervention: Individual education program
Number of subjects: 241

Group type: COMPARATOR
Intervention: Group education program
Number of subjects: 241

Group type: COMPARATOR
Intervention: Minimal instruction program
Number of subjects: 241

Group type: COMPARATOR
Intervention: All programs
Number of subjects: 241
Study: 8238148

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 mg) from 24 weeks' gestation until delivery
Number of subjects: 538

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 538
Study: 3807445

Group type: EXPERIMENTAL
Intervention: Pentazocine (75 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Codeine (100 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Diazepam (0.25 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pentazocine + Diazepam
Number of subjects: 10

Group type: COMPARATOR
Intervention: Codeine + Diazepam
Number of subjects: 10

Group type: COMPARATOR
Intervention: Opiates + Diazepam
Number of subjects: 10
Study: 31894843

Group type: EXPERIMENTAL
Intervention: Wuling capsule
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 29971999

Group type: EXPERIMENTAL
Intervention: Intradermal needling combined with tuina
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional tuina
Number of subjects: 90
Study: 27470569

Group type: EXPERIMENTAL
Intervention: Fluvastatin (80mg) plus Benazepril (10mg)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Fluvastatin (80mg)
Number of subjects: 92
Study: 24447629

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 112

Group type: COMPARATOR
Intervention: Ezetimibe/Simvastatin 10/40 mg
Number of subjects: 112
Study: 23662659

Group type: EXPERIMENTAL
Intervention: Static progressive stretch orthosis with physical therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Physical therapy alone
Number of subjects: 60
Study: 20128949

Group type: EXPERIMENTAL
Intervention: Life-review course 'Looking for Meaning'
Number of subjects: 171

Group type: COMPARATOR
Intervention: Movie (comparison group)
Number of subjects: 171
Study: 18559037

Group type: EXPERIMENTAL
Intervention: Unilateral t-tube insertion in one ear
Number of subjects: 7

Group type: COMPARATOR
Intervention: No treatment in the other ear (control)
Number of subjects: 7
Study: 15568188

Group type: EXPERIMENTAL
Intervention: New formula for sample size calculations for comparative clinical trials with Poisson or over-dispersed Poisson process data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Application of the formula to a trial for chronic granulomatous disease
Number of subjects: 0
Study: 11809161

Group type: EXPERIMENTAL
Intervention: Age transformation of hippocampus-amygdala formation (HAF) volume
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Age transformation of HAF volume
Number of subjects: 55

Group type: COMPARATOR
Intervention: Healthy control subjects (no intervention)
Number of subjects: 55
Study: 10522247

Group type: EXPERIMENTAL
Intervention: Buprenorphine (7.3 mg sublingual tablets)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Methadone (63 mg oral)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both Buprenorphine and Methadone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 20
Study: 8927531

Group type: EXPERIMENTAL
Intervention: Push handle height at 86.5% of shoulder height (1.191 +/- 0.034 m)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Push handle heights of 61%, 69.5%, 78%, 86.5%, and 95% of shoulder height
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low pushing handles
Number of subjects: 8
Study: 1836754

Group type: EXPERIMENTAL
Intervention: DMPA
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NET-EN
Number of subjects: 20
Study: 7000029

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine sulfate
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Fenfluramine hydrochloride
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 30866980

Group type: EXPERIMENTAL
Intervention: Educational intervention based on health belief model (HBM) delivered in four training sessions about physical activity and nutrition.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 0
Study: 27688313

Group type: EXPERIMENTAL
Intervention: Pharmacological pain treatments
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Nonpharmacological pain treatments
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Higher ability to communicate
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Fewer pain locations
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Longer duration in nursing home
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Higher dependency
Number of subjects: 125
Study: 26101174

Group type: EXPERIMENTAL
Intervention: Amifampridine phosphate salt (20 mg base equivalents per dose) under fed conditions
Number of subjects: 47

Group type: COMPARATOR
Intervention: Amifampridine phosphate salt (20 mg base equivalents per dose) under fasted conditions
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Amifampridine phosphate salt (20 mg base equivalents per dose)
Number of subjects: 47
Study: 25627992

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4 (n=86)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Ringer's lactate (n=25)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Ringer's lactate (500 ml preload)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Additional fluid boluses
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Fluid volume optimization
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Blood volume expansion
Number of subjects: 111
Study: 20678132

Group type: EXPERIMENTAL
Intervention: Immediately placed implants in sockets without periapical pathology (test group)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Immediately placed implants in sockets with periapical pathologies (control group)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 29
Study: 19321811

Group type: EXPERIMENTAL
Intervention: Virtual reality cognitive behavior therapy (VRCBT)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Wait list control (WLC)
Number of subjects: 88
Study: 17003842

Group type: EXPERIMENTAL
Intervention: Alterations in the vasoactive intestinal peptide (VIP) gene
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Alterations in the noncoding regions of the VIP gene
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Alterations in the coding regions of the VIP gene
Number of subjects: 10

Group type: COMPARATOR
Intervention: VIP gene alterations correlation with IPAH
Number of subjects: 10
Study: 14704545

Group type: EXPERIMENTAL
Intervention: Combined viscocanalostomy and cataract surgery (VCS group)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Cataract surgery alone (CSA group)
Number of subjects: 206
Study: 11309007

Group type: EXPERIMENTAL
Intervention: Lidocaine and adrenaline infiltration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline and adrenaline infiltration (Control)
Number of subjects: 8
Study: 9656847

Group type: EXPERIMENTAL
Intervention: SLS-free dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: SLS-containing dentifrice
Number of subjects: 0
Study: 7701262

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Injection sclerotherapy
Number of subjects: 0
Study: 3668124

Group type: EXPERIMENTAL
Intervention: Six-mixed grass-pollen allergoid
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Standardized orchard grass-pollen extract
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 30124753

Group type: EXPERIMENTAL
Intervention: Talazoparib (1 mg daily, orally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physician's choice of chemotherapy (PCT; capecitabine, eribulin, gemcitabine, or vinorelbine)
Number of subjects: 0
Study: 27799176

Group type: EXPERIMENTAL
Intervention: 1000 mg i.v. paracetamol
Number of subjects: 80

Group type: COMPARATOR
Intervention: 100 ml normal saline (placebo)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 24249722

Group type: COMPARATOR
Intervention: Thiazide diuretic-based therapy
Number of subjects: 6083

Group type: EXPERIMENTAL
Intervention: ACEI-based therapy
Number of subjects: 6083

Group type: EXPERIMENTAL
Intervention: Preexisting diabetes
Number of subjects: 6083

Group type: COMPARATOR
Intervention: Newly diagnosed diabetes
Number of subjects: 6083
Study: 22364647

Group type: EXPERIMENTAL
Intervention: ungrouped superimposed median beat (uSMB) method
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: grouped superimposed median beat (gSMB) method
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: both methods
Number of subjects: 38
Study: 20829700

Group type: EXPERIMENTAL
Intervention: morphine 1 mg/ml with metoclopramide 0.5 mg/ml and diphenhydramine 0.6 mg/ml (group 4)
Number of subjects: 200

Group type: COMPARATOR
Intervention: morphine 1 mg/ml (group 1)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: morphine 1 mg/ml with metoclopramide 0.5 mg/ml (group 2)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: morphine 1 mg/ml with diphenhydramine 0.6 mg/ml (group 3)
Number of subjects: 200
Study: 18270560

Group type: EXPERIMENTAL
Intervention: 20 microg AMA1-C1/Alhydrogel
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 80 microg AMA1-C1/Alhydrogel
Number of subjects: 36

Group type: COMPARATOR
Intervention: Haemophilus influenzae type b Hiberix vaccine
Number of subjects: 36
Study: 16181819

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 51

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 51
Study: 12559863

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 0
Study: 10692931

Group type: EXPERIMENTAL
Intervention: Retinoscopy at the end of cataract surgery
Number of subjects: 68

Group type: COMPARATOR
Intervention: Biometric measurements
Number of subjects: 68
Study: 8944106

Group type: EXPERIMENTAL
Intervention: Prilocaine 2% plain
Number of subjects: 75

Group type: COMPARATOR
Intervention: Lignocaine 1% and bupivacaine 0.5% with hyaluronidase
Number of subjects: 75
Study: 2008873

Group type: EXPERIMENTAL
Intervention: Olestra (20 g/d)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 6605890

Group type: EXPERIMENTAL
Intervention: Fentiazac suspension
Number of subjects: 50

Group type: COMPARATOR
Intervention: Benzidamine drops
Number of subjects: 50
Study: 31493105

Group type: EXPERIMENTAL
Intervention: Family-based exposure-focused treatment (FET)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 32
Study: 30445176

Group type: EXPERIMENTAL
Intervention: Small Changes, a weight gain prevention intervention
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Look AHEAD Intensive Lifestyle Intervention
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Lower-intensity bibliotherapy intervention
Number of subjects: 400
Study: 27367916

Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Ballistic stretching
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: PNF stretching
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 122
Study: 26318758

Group type: COMPARATOR
Intervention: CNTRL (unsupplemented pasture)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: FLAX‐1 (0.125% BW whole flaxseed)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: FLAX‐0 (0.7% BW cracked corn)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: FLAX‐2 (0.250% BW whole flaxseed)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Postmortem aging time (3, 14, and 56 days) with aerobic exposure (AE)
Number of subjects: 24
Study: 25205641

Group type: EXPERIMENTAL
Intervention: Upper airway stimulation via the hypoglossal nerve (therapy maintenance 'ON' group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Upper airway stimulation via the hypoglossal nerve (therapy withdrawal 'OFF' group)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Upper airway stimulation via the hypoglossal nerve (both groups at 18 months)
Number of subjects: 46
Study: 21729466

Group type: EXPERIMENTAL
Intervention: Universal Fe supplementation of 65 mg/d for two months (group II)
Number of subjects: 959

Group type: COMPARATOR
Intervention: Selective anaemia screening of high-risk women (control)
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Universal anaemia screening and treatment of anaemic women (group I)
Number of subjects: 959
Study: 19753635

Group type: EXPERIMENTAL
Intervention: Abciximab bolus-only (0.25 mg/kg)
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Abciximab bolus + infusion (12 hours)
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Not-randomized group (abciximab bolus and infusion)
Number of subjects: 1005
Study: 17888214

Group type: EXPERIMENTAL
Intervention: Computerized administration (PC)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Interviewer administration (IA)
Number of subjects: 138
Study: 15554742

Group type: EXPERIMENTAL
Intervention: 0.1% adapalene gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.025% tretinoin gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.1% tretinoin microsphere gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.05% tretinoin cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.1% tazarotene gel (once every two days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.1% tazarotene gel (once daily)
Number of subjects: 0
Study: 11442615

Group type: EXPERIMENTAL
Intervention: Topical silicone gel sheeting (applied 48 hours after surgery)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Routine postoperative care
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Topical silicone gel sheeting (following scar revision procedure)
Number of subjects: 2
Study: 10958249

Group type: EXPERIMENTAL
Intervention: Bromocriptine 1.25 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Haloperidol 3 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bromocriptine 1.25 mg + Haloperidol 3 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8032040

Group type: EXPERIMENTAL
Intervention: Glutaraldehyde inhalation challenge at 0.032 ppm
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Glutaraldehyde inhalation challenge at up to 0.32 ppm for 10 min (second series)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control days (unblinded workplace challenge)
Number of subjects: 1
Study: 2470577

Group type: EXPERIMENTAL
Intervention: 50 mg hydrocortisone
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 1079972

Group type: EXPERIMENTAL
Intervention: 2‐3 DPG‐enriched previously frozen, washed, concentrated red cells (2‐3 DPG 150 percent of normal)
Number of subjects: 22

Group type: COMPARATOR
Intervention: CPD‐stored or fresh blood (70 percent of normal 2‐3 DPG)
Number of subjects: 22
Study: 29750695

Group type: EXPERIMENTAL
Intervention: Proximal catheter location (n = 24)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Distal catheter location (n = 26)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Proximal catheter location
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 27131614

Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive strategy (fibrinolysis followed by transfer for PCI)
Number of subjects: 1701

Group type: COMPARATOR
Intervention: Primary PCI (PPCI)
Number of subjects: 1701

Group type: COMPARATOR
Intervention: PPCI
Number of subjects: 1701
Study: 24963599

Group type: EXPERIMENTAL
Intervention: Equine‐assisted therapy protocol (EAT), 16-week program, 2 hours of activity per week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study: 23145846

Group type: EXPERIMENTAL
Intervention: Individual financial incentives every 4 months for 5 periods
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Group financial incentives every 4 months for 5 periods
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Combined financial incentives every 4 months for 5 periods
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no financial incentives)
Number of subjects: 83
Study: 21098770

Group type: EXPERIMENTAL
Intervention: Endosonography (combined transesophageal and endobronchial ultrasound) followed by surgical staging if no nodal metastases found
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Endosonography followed by surgical staging
Number of subjects: 241

Group type: COMPARATOR
Intervention: Surgical staging
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Endosonography
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Endosonography and surgical staging
Number of subjects: 241
Study: 18482234

Group type: EXPERIMENTAL
Intervention: 1 mug.kg(‐1) IT fentanyl
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (plain 0.5% hyperbaric bupivacaine)
Number of subjects: 56
Study: 16603609

Group type: EXPERIMENTAL
Intervention: CHX (2%)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: CHX/COL (2%/2%)
Number of subjects: 385

Group type: COMPARATOR
Intervention: PLAC (placebo)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: CHX/COL
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: CHX
Number of subjects: 385
Study: 14561536

Group type: EXPERIMENTAL
Intervention: Mesigyna (50 mg norethisterone enanthate and 5 mg estradiol valerate)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Cyclofem (25 mg medroxyprogesterone acetate and 5 mg estradiol cypionate)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Ortho-Novum 1/35 (norethisterone 1 mg and ethinyl estradiol 35 microg)
Number of subjects: 378
Study: 10826048

Group type: EXPERIMENTAL
Intervention: Atraumatic restorative technique (ART)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional restorative technique
Number of subjects: 0
Study: 8778550

Group type: EXPERIMENTAL
Intervention: Active Recovery (AR) at a workload corresponding to 32% of maximal aerobic power
Number of subjects: 10

Group type: COMPARATOR
Intervention: Passive Recovery (PR)
Number of subjects: 10
Study: 1898892

Group type: EXPERIMENTAL
Intervention: Combined therapy (gonadotropin followed by pulsatile GnRH)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Pure exogenous follicle-stimulating hormone alone
Number of subjects: 8
Study: 6227542

Group type: EXPERIMENTAL
Intervention: Diprosalic Solution (0.64 mg betamethasone‐dipropionate plus 20 mg salicylic acid)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Betamethasone dipropionate solution (0.64 mg)
Number of subjects: 100
Study: 29920834

Group type: EXPERIMENTAL
Intervention: HEART Pathway
Number of subjects: 282

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 282